Germline 16p11.2 Microdeletion Predisposes to Neuroblastoma.

Area of Science:

• Genetics
• Pediatric Oncology
• Developmental Biology

Background:

• Neuroblastoma is a significant cause of pediatric cancer deaths, originating from the sympathetic nervous system.
• The genetic underpinnings of neuroblastoma are complex, with the role of rare germline variants not fully understood.
• Copy number variants (CNVs) are known to contribute to various genetic disorders and developmental phenotypes.

Purpose of the Study:

• To investigate the contribution of large, rare germline copy number variants (CNVs) to neuroblastoma risk.
• To identify specific genetic variants associated with neuroblastoma in a large, multi-ethnic pediatric cohort.

Main Methods:

• Genome-wide analysis of large (>500 kb), rare (<1%) germline CNVs in 5,585 neuroblastoma cases and 23,505 controls.
• Statistical analysis to identify CNVs significantly enriched in neuroblastoma cases.
• Whole-genome sequencing (WGS) for validation in tumor-normal pairs and analysis of parent-child trios to determine inheritance patterns.

Main Results:

• A 550-kb deletion on chromosome 16p11.2 was significantly associated with neuroblastoma (OR=13.9, P=3.34×10⁻⁹).
• This deletion, previously linked to neurodevelopmental disorders, occurred in 0.39% of cases versus 0.03% of controls.
• The deletion was confirmed via WGS and found to arise predominantly de novo.

Conclusions:

• The 16p11.2 deletion is a novel, significant risk factor for pediatric neuroblastoma.
• This finding expands the phenotypic spectrum of the 16p11.2 microdeletion syndrome to include cancer.
• Disruption of the 16p11.2 region may impact neurodevelopmental pathways relevant to both neurological conditions and neuroblastoma.